Navigation Links
Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:6/1/2010

es of paclitaxel and carboplatin on day one only, and on days one through five, either intravenous placebo or intravenous REOLYSIN at a dose of 3x10(10) TCID(50). Patients may continue to receive the trial combination therapy for up to eight, 21-day cycles and, thereafter, blinded placebo or blinded REOLYSIN until the patient has progressive disease or meets other criteria for removal from the trial. Oncolytics intends to conduct the first stage of the trial at approximately 25 centres in the U.S., U.K., and Belgium.

The primary endpoint for the trial is overall survival (OS); secondary endpoints include progression free survival (PFS), objective response rate (complete response (CR) + partial response (PR)) and duration of response, and safety and tolerability of REOLYSIN when administered in combination with paclitaxel and carboplatin. The first stage of the trial is designed to enroll 80 patients. The second stage is adaptive, and is designed to enroll between 100 and 400 patients with the most probable statistical enrolment being 195 patients in this stage. This adaptive trial design allows frequent data evaluation to determine if the probability of reaching a statistically significant endpoint has been achieved.

The decision to pursue a Phase 3 trial in head and neck cancers was predicated on positive results seen in the Company's U.K. Phase 1 and Phase 2 combination REOLYSIN and paclitaxel/carboplatin clinical trials, as well as significant preclinical work demonstrating synergy in combination with taxane or platinum-based drugs. Updated results from the U.K. Phase 1/2 trial reported in November 2009 demonstrated an overall response rate (PR and CR) of 42% and a total clinical benefit rate (PR + CR + stable disease) of 74%. The Company is currently conducting a confirmatory Phase 2 trial in the U.S. in patients with advanced head and n
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
2. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
3. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
4. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
5. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
6. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
7. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
8. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
9. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
10. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
11. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Crystal Diagnostics (CDx) ... that it has received AOAC-PTM Certifications for the six non-O157 ... and O145; collectively referred to as STEC or the “Big-6”) ... colony forming unit (cfu) per 325 g of raw ground ...
(Date:1/22/2015)... 22, 2015 Dr. Greg Leyer of UAS ... Scripps Natural Supplements Pre-Conference seminar on probiotics in San Diego, ... annual continuing education conference for health care professionals. This year’s ... topic of probiotics in health. Dr. Leyer spoke about the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
(Date:1/22/2015)... 22. 2015  Varian Medical Systems (NYSE: VAR ), ... for its commitment to sustainability with inclusion on a prestigious ... highest ranked healthcare equipment company among the Corporate Knights Global ... Economic Forum at Davos, Switzerland . ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... In a move designed to give Wisconsin a competitive ... a partnership agreement with the Wisconsin Alumni Research ... research at non-profit and academic institutions in Wisconsin a ... held by WARF. , ,In what the administration called ...
... in the first televised debate in Wisconsin's campaign for governor ... asked Gov. Jim Doyle and challenger Mark ... Beene, who had worked for Pabst Brewery before its 1997 ... closing all over the place" - and he wanted to ...
... Wis. - The Center for International Blood and ... Wisconsin has won a contract worth $6,180,029 to collect ... cell transplants that use cells from bone marrow or cord ... part of the U.S. Department of Health and Human ...
Cached Biology Technology:Doyle, WARF announce partnership to lure stem cell companies 2Doyle, WARF announce partnership to lure stem cell companies 3Candidates' sparring over jobs focuses debate on right issue 2Candidates' sparring over jobs focuses debate on right issue 3Medical College to build $6M transplant database 2
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" report ... Facial recognition is a technology used ... the overall facial feature of a person such as ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ...
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched an innovative ... that enhances care coordination among social service and care providers ... second $1 million grant from the Alliance Healthcare Foundation to ... be recognized as a "Live Well San Diego" partner on ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... in on finding an effective bait to get ahead ... is now killing not only lodgepole pine forests, but ... Research Chair in Forest Entomology in the University of ... emitted by the pest in North America,s lodgepole and ...
... multi-model-based assessment of so-called Durban Platform scenarios, conducted by ... Institute for Climate Impact Research (PIK) and the Fondazione ... is the current negotiation track at the Warsaw climate ... by 2015 to come into effect in 2020. ...
... new research shows that the Plasmodium vivax ... in 2010, may be "rapidly evolving" to overcome the natural ... Africans, scientists reported today at the annual meeting of the ... In large swaths of sub-Saharan Africa, some 95 ...
Cached Biology News:Bait research focused on outsmarting destructive beetle 2Success of climate talks vital for 2°C target 2Success of climate talks vital for 2°C target 3New research finds potential risk for millions in Africa believed resistant to vivax malaria 2New research finds potential risk for millions in Africa believed resistant to vivax malaria 3New research finds potential risk for millions in Africa believed resistant to vivax malaria 4
... Kinase (PNK) catalyzes the transfer of ... 5'-hydroxyl of single- and double-stranded DNA, ... also removes the 3'-phosphate from 3'-phosphoryl ... 5'-diphosphates to form a 3'-hydroxyl group. ...
MOUSE ANTI GTP BINDING PROTEIN...
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to info@rpeptide.com...
Maxi XL Hybridization Oven for Extra Large bottles. 6 bottle (70 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 extra large bottles, pack o...
Biology Products: